Albany Molecular Files Form 8-K Disclosing Termination Of Development Of BMS-820836 With Bristol-Myers Squibb

Albany Molecular Research, Inc. (NASDAQ: AMRI ) has been informed by its license partner, Bristol-Myers Squibb (NYSE: BMY ), of its decision to terminate development of BMS-820836, an investigational triple reuptake inhibitor in phase II clinical development for Treatment Resistant Depression (TRD). This decision is being announced today